TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07654374: A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1100 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT07654374 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07654374 Rescue Dossier →